Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study.
30-day mortality
COVID-19
SARS-CoV-2
biomarker
copeptin
prognostic markers
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
received:
08
01
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Activation of the vasopressin system plays a key role for the maintenance of osmotic, cardiovascular, and stress hormone homeostasis during disease. We investigated levels of copeptin, the C-terminal segment of the vasopressin prohormone, that mirrors the production rate of vasopressin in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We measured levels of copeptin on admission and after days 3/4, 5/6, and 7/8 in 74 consecutive hospitalized adult COVID-19 patients and compared its prognostic accuracy to that of patients with community-acquired pneumonia (n = 876) and acute or chronic bronchitis (n = 371) from a previous study by means of logistic regression analysis. The primary endpoint was all-cause 30-day mortality. Median admission copeptin levels in COVID-19 patients were almost 4-fold higher in nonsurvivors compared with survivors (49.4 pmol/L [iterquartile range (IQR) 24.9-68.9 pmol/L] vs 13.5 pmol/L [IQR 7.0-26.7 pmol/L]), resulting in an age- and gender-adjusted odds ratio of 7.0 (95% confidence interval [CI] 1.2-40.3), A pronounced activation of the vasopressin system in COVID-19 patients is associated with an adverse clinical course in COVID-19 patients. This finding, however, is not unique to COVID-19 but similar to other types of respiratory infections.
Sections du résumé
BACKGROUND
BACKGROUND
Activation of the vasopressin system plays a key role for the maintenance of osmotic, cardiovascular, and stress hormone homeostasis during disease. We investigated levels of copeptin, the C-terminal segment of the vasopressin prohormone, that mirrors the production rate of vasopressin in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
METHODS
METHODS
We measured levels of copeptin on admission and after days 3/4, 5/6, and 7/8 in 74 consecutive hospitalized adult COVID-19 patients and compared its prognostic accuracy to that of patients with community-acquired pneumonia (n = 876) and acute or chronic bronchitis (n = 371) from a previous study by means of logistic regression analysis. The primary endpoint was all-cause 30-day mortality.
RESULTS
RESULTS
Median admission copeptin levels in COVID-19 patients were almost 4-fold higher in nonsurvivors compared with survivors (49.4 pmol/L [iterquartile range (IQR) 24.9-68.9 pmol/L] vs 13.5 pmol/L [IQR 7.0-26.7 pmol/L]), resulting in an age- and gender-adjusted odds ratio of 7.0 (95% confidence interval [CI] 1.2-40.3),
CONCLUSIONS
CONCLUSIONS
A pronounced activation of the vasopressin system in COVID-19 patients is associated with an adverse clinical course in COVID-19 patients. This finding, however, is not unique to COVID-19 but similar to other types of respiratory infections.
Identifiants
pubmed: 34056499
doi: 10.1210/jendso/bvab045
pii: bvab045
pmc: PMC7989362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvab045Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Thorax. 2010 Mar;65(3):208-14
pubmed: 20335288
Anesthesiology. 1992 Oct;77(4):662-8
pubmed: 1329579
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Intensive Care Med. 2014 Oct;40(10):1499-508
pubmed: 25223852
Am J Physiol. 1962 Sep;203:425-8
pubmed: 13911353
BMC Neurol. 2010 May 26;10:34
pubmed: 20504314
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
Biomed Res Int. 2016;2016:3624730
pubmed: 27366743
Ann Trop Paediatr. 1992;12(4):455-62
pubmed: 1283678
Shock. 2007 Aug;28(2):219-26
pubmed: 17515850
Swiss Med Wkly. 2010 Sep 24;140:w13101
pubmed: 20872295
Clin Chem. 2005 Oct;51(10):1823-9
pubmed: 16099941
Clin Chem Lab Med. 2021 Jan 08;59(5):995-1004
pubmed: 33554516
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Ann N Y Acad Sci. 1995 Dec 29;771:192-203
pubmed: 8597399
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E882-E885
pubmed: 32396497
Kidney Int. 1986 Jun;29(6):1237-47
pubmed: 3747337
Ann Neurol. 2009 Dec;66(6):799-808
pubmed: 20035506
Chest. 2007 Apr;131(4):1058-67
pubmed: 17426210
Stroke. 2010 Jul;41(7):1564-7
pubmed: 20508186
Peptides. 2005 Dec;26(12):2500-4
pubmed: 15922490
J Headache Pain. 2017 Dec;18(1):21
pubmed: 28197843
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32232480
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Am J Physiol. 1983 Jan;244(1):E72-82
pubmed: 6295182
BMC Health Serv Res. 2007 Jul 05;7:102
pubmed: 17615073
BMC Anesthesiol. 2014 Nov 15;14:102
pubmed: 25419180
Biochem Soc Trans. 1979 Oct;7(5):861-5
pubmed: 510730
Compr Physiol. 2016 Mar 15;6(2):603-21
pubmed: 27065163
Crit Care. 2005;9(6):R816-24
pubmed: 16356231
Crit Care. 2010;14(3):R106
pubmed: 20529344
Crit Care. 2008;12(1):R11
pubmed: 18252006
Neurology. 2013 Apr 2;80(14):1278-86
pubmed: 23468541
J Endocrinol Invest. 2020 Aug;43(8):1137-1139
pubmed: 32451971
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Kidney Int Suppl. 1988 Oct;26:S48-51
pubmed: 2974097
JAMA. 2009 Sep 9;302(10):1059-66
pubmed: 19738090
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Eur J Clin Invest. 2007 Feb;37(2):145-52
pubmed: 17217381
Swiss Med Wkly. 2020 Jul 15;150:w20316
pubmed: 32668007
Clin Chim Acta. 2010 Dec 14;411(23-24):1929-34
pubmed: 20699094
Clin Chem. 2006 Jan;52(1):112-9
pubmed: 16269513
Stroke. 2014 Oct;45(10):2918-23
pubmed: 25169950